UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

British journal of cancer, 2013-04, Vol.108 (8), p.1571-1578

2013

Volltextzugriff (PDF)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

British journal of cancer, 2014-06, Vol.110 (12), p.2821-2828

2014

Volltextzugriff (PDF)

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial

Japanese journal of clinical oncology, 2013-06, Vol.43 (6), p.616-628

2013

Volltextzugriff (PDF)

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Annals of oncology, 2010-02, Vol.21 (2), p.297-304

2010

Volltextzugriff (PDF)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

British journal of cancer, 2012-10, Vol.107 (8), p.1277-1285

2012

Volltextzugriff (PDF)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

British journal of cancer, 2012-10, Vol.107 (8), p.1268-1276

2012

Volltextzugriff (PDF)

359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib

European journal of cancer (1990), 2014-11, Vol.50, p.116-116

2014

Volltextzugriff (PDF)

Social determinants of health in total knee arthroplasty: are social factors associated with increased 30-day post-discharge cost of care and length of stay?

The bone & joint journal, 2021-06, Vol.103-B (6 Supple A), p.113-118

2021

Volltextzugriff (PDF)

Does acid etching enhance remineralisation of arrested white spot lesions?

European archives of paediatric dentistry, 2014-12, Vol.15 (6), p.413-419

2014

Volltextzugriff (PDF)

7103 ORAL Association of Single Nucleotide Polymorphisms (SNPs) in VEGF Pathway Genes With Progression-free Survival (PFS) and Blood Pressure (BP) in Metastatic Renal Cell Carcinoma (mRCC) in the Phase 3 Trial of Axitinib Versus Sorafenib (AXIS Trial)

European journal of cancer (1990), 2011, Vol.47, p.S505-S505

2011

Volltextzugriff (PDF)

3006 POSTER DISCUSSION Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC)

European journal of cancer (1990), 2011, Vol.47, p.S224-S224

2011

Volltextzugriff (PDF)

P151 - Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

European urology, 2024-03, Vol.85, p.S213-S214

2024

Volltextzugriff (PDF)

Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

European urology, 2024-03, Vol.85, p.S213-S214

2024

Volltextzugriff (PDF)

P088 Prostate-specific antigen dynamics from the phase 3 EMBARK trial: A post hoc analysis

European urology open science (Online), 2024-11, Vol.69, p.107-108

2024

Volltextzugriff (PDF)

Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results

Annals of oncology, 2016-10, Vol.27, p.vi266-vi266

2016

Volltextzugriff (PDF)

843PLONG-TERM SAFETY WITH AXITINIB IN ADVANCED RENAL CELL CARCINOMA

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv293-iv294

2014

Volltextzugriff (PDF)

Long-Term Safety with Axitinib in Advanced Renal Cell Carcinoma

Annals of oncology, 2014-09, Vol.25, p.iv293

2014

Volltextzugriff (PDF)

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS4-07-GS4-07

2018

Volltextzugriff (PDF)

Long-term duration of axitinib treatment in advanced renal cell carcinoma

Annals of oncology, 2016-10, Vol.27, p.vi287-vi287

2016

Volltextzugriff (PDF)

Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27, p.vi449-vi449

2016

Volltextzugriff (PDF)

1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC)

European journal of cancer supplements, 2009, Vol.7 (2), p.130-130

2009

Volltextzugriff (PDF)

Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors

Annals of oncology, 2012-09, Vol.23, p.ix262

2012

Volltextzugriff (PDF)

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

British journal of cancer, 2014-02, Vol.110 (4), p.875-881

2014

Volltextzugriff (PDF)

Design aspects and performance of cost-efficient packaged power amplifiers

2015 IEEE International Conference on Microwaves, Communications, Antennas and Electronic Systems (COMCAS), 2015, p.1-4

2015

Volltextzugriff (PDF)

4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib

European journal of cancer supplements, 2007, Vol.5 (4), p.300-300

2007

Volltextzugriff (PDF)

1 – 25 von 499

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(439)
Mit Volltextzugriff
(428)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib

Social determinants of health in total knee arthroplasty: are social factors associated with increased 30-day post-discharge cost of care and length of stay?

Does acid etching enhance remineralisation of arrested white spot lesions?

7103 ORAL Association of Single Nucleotide Polymorphisms (SNPs) in VEGF Pathway Genes With Progression-free Survival (PFS) and Blood Pressure (BP) in Metastatic Renal Cell Carcinoma (mRCC) in the Phase 3 Trial of Axitinib Versus Sorafenib (AXIS Trial)

3006 POSTER DISCUSSION Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC)

P151 - Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

P088 Prostate-specific antigen dynamics from the phase 3 EMBARK trial: A post hoc analysis

Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results

843PLONG-TERM SAFETY WITH AXITINIB IN ADVANCED RENAL CELL CARCINOMA

Long-Term Safety with Axitinib in Advanced Renal Cell Carcinoma

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

Long-term duration of axitinib treatment in advanced renal cell carcinoma

Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC)

Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

Design aspects and performance of cost-efficient packaged power amplifiers

4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib

Suchergebnisse filtern